Deals & Cases

Schellenberg Wittmer advises Santhera Pharmaceuticals in exclusive License Agreement with Polyphor

15.02.2018

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. On 15 January 2018, Santhera Pharmaceuticals announced that it had entered into an agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other pulmonary diseases.

Under the agreement, Santhera obtains the worldwide, exclusive rights to develop and commercialize POL6014, for an initial payment of CHF 6.5 million and additional cash payments of up to CHF 121 million contingent to future development, regulatory and particularly sales milestones.

Schellenberg Wittmer is advising Santhera Pharmaceuticals on this matter.

The team consists of Philipp Groz (IP / Life Sciences), Pascal Hubli (Corporate/M&A), Michael Nordin and Petra Hess (both Tax). 

Downloads

  View pdf
 

Subscribe to our Updates

*Required fields

Monthly selected key topics from our practice areas and sectors, plus Newsflashes on current events.
Monthly email with the latest updates on and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
A regular look (1 – 2 per year) from a unique M&A perspective on legal changes, economic developments and societal trends in Switzerland.
Regular insights on Swiss and international trends and legal developments in the construction industry.
Concise analyses of key trends in the fast moving world of corporate governance for the boards of Swiss companies.